A trial looking at rilvegostomig and chemotherapy for advanced non small cell lung cancer (ARTEMIDE-Lung02)

Overview

Cancer types:

Lung cancer, Non small cell lung cancer (NSCLC), Secondary cancers

Status:

Open

Phase:

Phase 3

Details

This trial is looking at rilvegostomig and chemotherapy for non small cell lung cancer that has spread. It is comparing this to pembrolizumab and chemotherapy.

It is for people who:

have a type of non small cell lung cancer called
are having their first treatment for cancer that has spread to another part of the body
have cancer cells with a protein called PD-L1

You pronounce rilvegostomig as ril–veh–gost-oh-mig.

Recruitment start: 21 November 2024

Recruitment end: 15 May 2028